RT Journal Article
SR Electronic
T1 Deficiency of the minor spliceosome component U4atac snRNA secondarily results in ciliary defects
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.12.21266616
DO 10.1101/2021.12.12.21266616
A1 Khatri, Deepak
A1 Putoux, Audrey
A1 Cologne, Audric
A1 Kaltenbach, Sophie
A1 Besson, Alicia
A1 Bertiaux, Eloïse
A1 Guguin, Justine
A1 Fendler, Adèle
A1 Dupont, Marie A.
A1 Benoit-Pilven, Clara
A1 Grotto, Sarah
A1 Ruaud, Lyse
A1 Michot, Caroline
A1 Castelle, Martin
A1 Guët, Agnès
A1 Guibaud, Laurent
A1 Hamel, Virginie
A1 Bordonné, Rémy
A1 Leutenegger, Anne-Louise
A1 Attié-Bitach, Tania
A1 Edery, Patrick
A1 Mazoyer, Sylvie
A1 Delous, Marion
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2021.12.12.21266616.abstract
AB In the human genome, about 750 genes contain one intron excised by the minor spliceosome. This spliceosome comprises its own set of snRNAs, among which U4atac. Its non-coding gene, RNU4ATAC, has been found mutated in Taybi-Linder (MOPD1/TALS), Roifman (RFMN) and Lowry-Wood syndromes (LWS). These rare developmental disorders, whose physiopathological mechanisms remain unsolved, associate ante- and post-natal growth retardation, microcephaly, skeletal dysplasia, intellectual disability, retinal dystrophy and immunodeficiency. Here, we report a homozygous RNU4ATAC mutation in the Stem II domain, n.16G>A, in two unrelated patients presenting with both typical traits of the Joubert syndrome (JBTS), a well-characterized ciliopathy, and of TALS/RFMN/LWS, thus widening the clinical spectrum of RNU4ATAC-associated disorders and indicating ciliary dysfunction as a mechanism downstream of minor splicing defects. This finding is supported by alterations of primary cilium function in TALS and JBTS/RFMN fibroblasts, as well as by u4atac zebrafish model, which exhibit ciliopathy-related phenotypes and ciliary defects. Altogether, our data indicate that alteration of cilium biogenesis is part of the physiopathological mechanisms of TALS/RFMN/LWS, secondarily to defects of minor intron splicing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by CNRS, Inserm, Universite de Montpellier, Universite Paris 7 and Universite Lyon 1 through recurrent funding, the Fondation Maladies Rares ('Small Animal Models and Rare Diseases' program, no. 20161207), the Agence Nationale de la Recherche (no. ANR-18CE12-0007-01) grants. E.B. was supported by an EMBO long-term fellowship (ALTF-284-2019) and the Novartis Foundation for medical-biological Research (18B112).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Comite de protection des Personnes Sud-Est IV gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript